ArticleACS central science2021
Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.
Open access · diamondAbstract read
In one paragraph
Article in ACS central science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review.Journal of biomolecular structure & dynamics · 2022Pooled it
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.The Journal of antimicrobial chemotherapy · 2021Pooled it
- Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.The Journal of antimicrobial chemotherapy · 2020Trial
- Insights into SARS-CoV-2 replication controlActa pharmaceutica Sinica. B · 2026Article
- A dual-branch graph neural network architecture for drug-target binding affinity prediction.Scientific reports · 2026Article
- A Multi-modal Drug Target Affinity Prediction Based on Graph Features and Pre-trained Sequence Embeddings.Interdisciplinary sciences, computational life sciences · 2025Article
- Recent trends in ionic liquid-mediated synthesis of thiazoles: toward greener methodologies.RSC advances · 2025Review
- Dual-Site Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase by Small Molecules Able to Block Viral Replication Identified through a Computer-Aided Drug Discovery Approach.ACS infectious diseases · 2025Article
- Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Interference of small compounds and MgScientific reports · 2024Article
- An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease.Microbiology spectrum · 2024Article
- Systematic Studies on the Anti-SARS-CoV-2 Mechanisms of Tea Polyphenol-Related Natural Products.ACS omega · 2024Article
- Dopamine Inhibits the Expression of Hepatitis B Virus Surface and e Antigens by Activating the JAK/STAT Pathway and Upregulating Interferon-stimulated Gene 15 Expression.Journal of clinical and translational hepatology · 2024Article
- BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.Antimicrobial agents and chemotherapy · 2024Article
- Usp25-Erlin1/2 activity limits cholesterol flux to restrict virus infection.Developmental cell · 2023Article
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.Molecular aspects of medicine · 2023Review
- Bioinformatics-based investigation on the genetic influence between SARS-CoV-2 infections and idiopathic pulmonary fibrosis (IPF) diseases, and drug repurposing.Scientific reports · 2023Article
- In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing.Journal of molecular modeling · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 10 institutions in 6 countries.
Ho Sing LoSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.ORCID 0000-0003-2636-4972
Kenrie Pui Yan HuiSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Hei-Ming LaiDepartment of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Xu HeSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Khadija Shahed KhanSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Simranjeet KaurDepartment of Chemistry, Faculty of Science, Hong Kong Baptist University, Kowloon Tong, Hong Kong.
Junzhe HuangDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Zhongqi LiDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Anthony K N ChanDepartment of Systems Biology, Beckman Research Institute, City of Hope, Duarte, California 91010, United States.ORCID 0000-0002-7091-1294
Hayley Hei-Yin CheungSchool of Life Sciences, Centre for Protein Science and Crystallography, State Key Laboratory of Agrobiotechnology, Faculty of Science, The Chinese University of Hong Kong, Shatin, Hong Kong.
Ka-Chun NgSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.ORCID 0000-0001-7016-3209
John Chi Wang HoSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Yu Wai ChenDepartment of Applied Biology and Chemical Technology and the State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.
Bowen MaSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Peter Man-Hin CheungSchool of Public Health, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Donghyuk ShinBuchmann Institute for Molecular Life Sciences, Goethe University, 60323 Frankfurt am Main, Germany.
Kaidao WangProtein Production Department, GenScript Biotech Corporation, Nanjing, Jiangsu Province 211100, China.
Meng-Hsuan LeeInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan 115.
Barbara SeliskoLaboratoire d'Architecture et Fonction des Macromolécules Biologiques (AFMB), Centre National de la Recherche Scientifique, Aix-Marseille Université, 13007 Marseille, France.
Cecilia EydouxLaboratoire d'Architecture et Fonction des Macromolécules Biologiques (AFMB), Centre National de la Recherche Scientifique, Aix-Marseille Université, 13007 Marseille, France.
Jean-Claude GuillemotLaboratoire d'Architecture et Fonction des Macromolécules Biologiques (AFMB), Centre National de la Recherche Scientifique, Aix-Marseille Université, 13007 Marseille, France.
Bruno CanardLaboratoire d'Architecture et Fonction des Macromolécules Biologiques (AFMB), Centre National de la Recherche Scientifique, Aix-Marseille Université, 13007 Marseille, France.
Kuen-Phon WuInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan 115.ORCID 0000-0002-1525-6004
Po-Huang LiangInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan 115.ORCID 0000-0003-1207-5256
Ivan DikicBuchmann Institute for Molecular Life Sciences, Goethe University, 60323 Frankfurt am Main, Germany.ORCID 0000-0001-8156-9511
Zhong ZuoSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.ORCID 0000-0002-6976-6157
Francis K L ChanDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
David S C HuiDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Vincent C T MokDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Kam-Bo WongSchool of Life Sciences, Centre for Protein Science and Crystallography, State Key Laboratory of Agrobiotechnology, Faculty of Science, The Chinese University of Hong Kong, Shatin, Hong Kong.ORCID 0000-0002-6984-5373
Chris Ka Pun MokHKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Shatin, Hong Kong.
Ho KoDepartment of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Wei Shen AikDepartment of Chemistry, Faculty of Science, Hong Kong Baptist University, Kowloon Tong, Hong Kong.
Michael Chi Wai ChanSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Wai-Lung NgSchool of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.ORCID 0000-0003-2892-6318
Chinese University of Hong Kong · HKAix-Marseille Université · FRInstitute of Biological Chemistry, Academia Sinica · TWGoethe University Frankfurt · DEHong Kong Baptist University · HKHong Kong Science and Technology Parks Corporation · HKUniversity of Hong Kong · HKCity of Hope · USHKU-Pasteur Research Pole · HKHong Kong Polytechnic University · HK
Funding
NIAID NIH HHS HHSN272201400006C
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global threat to human health. Using a multidisciplinary approach, we identified and validated the hepatitis C virus (HCV) protease inhibitor simeprevir as an especially promising repurposable drug for treating COVID-19. Simeprevir potently reduces SARS-CoV-2 viral load by multiple orders of magnitude and synergizes with remdesivir
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.